ARTICLE | Company News
arGEN-X, Leo Pharma deal
June 22, 2015 7:00 AM UTC
arGEN-X granted Leo exclusive, worldwide rights to develop and commercialize ARGX-112, a preclinical antibody to treat inflammation-related skin diseases. arGEN-X will receive EUR4.5 million ($5 mill...